Patient and Physician Perspectives on Biosimilar Use
The perspectives of patients and physicians play a pivotal role in the acceptance and integration of biosimilars into everyday clinical practice. Despite strong regulatory assurances of biosimilarity in terms of safety, efficacy, and quality, perceptions and confidence levels among healthcare providers and patients significantly influence prescribing behaviors, switching decisions, and overall market uptake. For physicians, biosimilars represent an opportunity to offer cost-effective treatment options, expand patient access, and optimize healthcare resources. However, concerns often linger regarding the clinical equivalence of biosimilars, especially in complex therapeutic areas such as oncology, rheumatology, and immunology. Many clinicians express caution about switching stable patients from originator biologics to biosimilars, largely due to a lack of long-term real-world data, fears about immunogenicity, or the perception that even minor structural differences might impact clinical outcomes. These concerns are particularly evident in regions where biosimilars are newly introduced, or where regulatory guidance on interchangeability and substitution is limited or inconsistent. Physicians’ willingness to prescribe biosimilars is heavily influenced by their level of education and experience with these products. Continuing medical education, access to comparative data, and positive clinical experiences can help shift attitudes from skepticism to acceptance. Endorsement by professional societies and inclusion of biosimilars in clinical guidelines also provide reassurance and promote wider adoption.
Related Conference of Patient and Physician Perspectives on Biosimilar Use
20th World Congress on Biomarkers, Cancer Therapy & Clinical Research
41st International Conference on Next-Gen Biotechnology and Applications
Patient and Physician Perspectives on Biosimilar Use Conference Speakers
Recommended Sessions
- Advancements in Biosimilar Development Technologies
- Artificial Intelligence and Digital Tools in Biotherapeutics
- Biobetters: The Next Generation of Biologics
- Biosimilar Market Access and Reimbursement Policies
- Biosimilars in Oncology and Autoimmune Diseases
- Biosimilars in Rare and Orphan Diseases
- Clinical Trials & Comparability Studies for Biosimilars
- Collaborative Models in Biosimilar Development
- Cost-Effectiveness and Health Economics of Biosimilars
- Evolving Trends and Innovations in Biosimilar Development and Access
- Formulation and Delivery Systems for Biologics
- Future Biotherapeutics: Cell and Gene Therapies
- Future of Monoclonal Antibodies and Fusion Proteins
- Global Trends and Challenges in Biosimilar Adoption
- Immunogenicity Assessment and Risk Management
- Interchangeability and Substitution Policies
- Manufacturing and Quality Control of Biosimilars
- Patient and Physician Perspectives on Biosimilar Use
- Pharmacovigilance and Post-Marketing Surveillance
- Regulatory Pathways and Global Harmonization
Related Journals
Are you interested in
- Advancements in Analytical Techniques - ANALYTICA ACTA 2026 (France)
- Advancements in Biosimilar Development Technologies - Biosimilars 2026 (France)
- Advances in Genomic Biotechnology - Biotechnology 2025 (Spain)
- Agriculture Biotechnology - Euro Biotechnology 2026 (Italy)
- Analytical Challenges in Personalized Medicine - ANALYTICA ACTA 2026 (France)
- Analytical Chemistry in Agriculture - ANALYTICA ACTA 2026 (France)
- Analytical Chemistry in the Energy Sector - ANALYTICA ACTA 2026 (France)
- Analytical Techniques for Biotechnology - ANALYTICA ACTA 2026 (France)
- Analytical Techniques in Material Science - ANALYTICA ACTA 2026 (France)
- Animal Biotechnology - Euro Biotechnology 2026 (Italy)
- Artificial Intelligence and Digital Tools in Biotherapeutics - Biosimilars 2026 (France)
- Automation in Bioanalytical Laboratories - ANALYTICA ACTA 2026 (France)
- Bio-Safety and Bioethics - Euro Biotechnology 2026 (Italy)
- Bioanalytical Method Development and Validation - ANALYTICA ACTA 2026 (France)
- Biobetters: The Next Generation of Biologics - Biosimilars 2026 (France)
- Bioinformatics & Computational Biology - Euro Biotechnology 2026 (Italy)
- Bioinformatics and Computational Approaches - ANALYTICA ACTA 2026 (France)
- Biomaterials - Euro Biotechnology 2026 (Italy)
- Biomedical Biotechnology - Biotechnology 2025 (Spain)
- Biomedical Engineering & Applications - Euro Biotechnology 2026 (Italy)
- Biopharmaceuticals and Biologics - ANALYTICA ACTA 2026 (France)
- Biopharmaceuticals and Biosimilars - Biotechnology 2025 (Spain)
- Bioprocess and Fermentation Technology - Euro Biotechnology 2026 (Italy)
- Bioremediation and Biodegradation - Euro Biotechnology 2026 (Italy)
- Biosimilar Market Access and Reimbursement Policies - Biosimilars 2026 (France)
- Biosimilars in Oncology and Autoimmune Diseases - Biosimilars 2026 (France)
- Biosimilars in Rare and Orphan Diseases - Biosimilars 2026 (France)
- Biotechnology - Euro Biotechnology 2026 (Italy)
- Biotechnology and Global Health - Biotechnology 2025 (Spain)
- Biotechnology Applications - Euro Biotechnology 2026 (Italy)
- Biotechnology in Agriculture - Biotechnology 2025 (Spain)
- Biotechnology in Dentistry - Euro Biotechnology 2026 (Italy)
- Chemical Analysis and Sensing - ANALYTICA ACTA 2026 (France)
- Clinical and Forensic Analysis - ANALYTICA ACTA 2026 (France)
- Clinical Trials & Comparability Studies for Biosimilars - Biosimilars 2026 (France)
- Collaborative Models in Biosimilar Development - Biosimilars 2026 (France)
- Computational and Systems Biology - Biotechnology 2025 (Spain)
- Cost-Effectiveness and Health Economics of Biosimilars - Biosimilars 2026 (France)
- Data Integrity and Compliance in Analytical Chemistry - ANALYTICA ACTA 2026 (France)
- Emerging Contaminants and Analytical Challenges - ANALYTICA ACTA 2026 (France)
- Emerging Trends in Analytical and Bioanalytical Techniques - ANALYTICA ACTA 2026 (France)
- Environmental Analysis - ANALYTICA ACTA 2026 (France)
- Environmental Biotechnology - Biotechnology 2025 (Spain)
- Environmental Biotechnology - Euro Biotechnology 2026 (Italy)
- Enzyme and Protein Engineering - Euro Biotechnology 2026 (Italy)
- Evolving Trends and Innovations in Biosimilar Development and Access - Biosimilars 2026 (France)
- Food and Beverage Analysis - ANALYTICA ACTA 2026 (France)
- Food and Feed Biotechnology - Euro Biotechnology 2026 (Italy)
- Formulation and Delivery Systems for Biologics - Biosimilars 2026 (France)
- Future Biotherapeutics: Cell and Gene Therapies - Biosimilars 2026 (France)
- Future of Monoclonal Antibodies and Fusion Proteins - Biosimilars 2026 (France)
- Future Trends in Biotechnology - Biotechnology 2025 (Spain)
- Genetics and Molecular biotechnology - Euro Biotechnology 2026 (Italy)
- Genomics and Molecular Biology Analysis - ANALYTICA ACTA 2026 (France)
- Global Trends and Challenges in Biosimilar Adoption - Biosimilars 2026 (France)
- High-Resolution Techniques - ANALYTICA ACTA 2026 (France)
- Imaging Techniques and Microscopy - ANALYTICA ACTA 2026 (France)
- Immunogenicity Assessment and Risk Management - Biosimilars 2026 (France)
- Industrial and Manufacturing Biotechnology - Euro Biotechnology 2026 (Italy)
- Industrial Biotechnology - Biotechnology 2025 (Spain)
- Industrial Scale-Up and Bioprocessing - Biotechnology 2025 (Spain)
- Instrumentation and Automation in Analytical Chemistry - ANALYTICA ACTA 2026 (France)
- Interchangeability and Substitution Policies - Biosimilars 2026 (France)
- Manufacturing and Quality Control of Biosimilars - Biosimilars 2026 (France)
- Marine Biotechnology - Biotechnology 2025 (Spain)
- Marine Biotechnology - Euro Biotechnology 2026 (Italy)
- Medical Biotechnology - Euro Biotechnology 2026 (Italy)
- Metabolomics and Proteomics - ANALYTICA ACTA 2026 (France)
- Microbial Biotechnology - Euro Biotechnology 2026 (Italy)
- Microbial Biotechnology - Biotechnology 2025 (Spain)
- Nano Biotechnology - Euro Biotechnology 2026 (Italy)
- Nanomaterials and Nanotechnology in Analysis - ANALYTICA ACTA 2026 (France)
- Oncolytic Biotechnology - Euro Biotechnology 2026 (Italy)
- Patient and Physician Perspectives on Biosimilar Use - Biosimilars 2026 (France)
- Pharmaceutical Analysis - ANALYTICA ACTA 2026 (France)
- Pharmaceutical Biotechnology and Drug Design - Euro Biotechnology 2026 (Italy)
- Pharmacovigilance and Post-Marketing Surveillance - Biosimilars 2026 (France)
- Plant and Forest Biotechnology - Euro Biotechnology 2026 (Italy)
- Quality by Design (QbD) in Analytical Method Development - ANALYTICA ACTA 2026 (France)
- Regenerative Medicine and Analytical Techniques - ANALYTICA ACTA 2026 (France)
- Regulatory Pathways and Global Harmonization - Biosimilars 2026 (France)
- Spectroscopic Techniques - ANALYTICA ACTA 2026 (France)
- Stem Cell and Regenerative Medicine - Biotechnology 2025 (Spain)
- Stem Cell Biotechnology and Regenerative Medicine - Euro Biotechnology 2026 (Italy)
- Surface and Interface Analysis - ANALYTICA ACTA 2026 (France)
- Synthetic Biology and Bioengineering - Biotechnology 2025 (Spain)
- Vaccine Development and Immunotherapy - Biotechnology 2025 (Spain)
- Workshops and Hands-On Training - ANALYTICA ACTA 2026 (France)